Advertisement

Topics

MatBA - Mature B-cell neoplasm array - Biotech, Pharma and Life Science Channel

23:42 EDT 28th June 2017 | BioPortfolio

Mature B-cell neoplasms arise in B-cells that have entered germinal centers within lymph nodes as part of the immune response. They display great heterogeneity at the clinical, pathologic, and genetic levels and represent 6-7% and 5-6% of all new estimated cancer cases and deaths respectively in the US in 2009. They are the fifth most common neoplasm in both males and females, and of the 103,960 estimated new cases in 2009, 20,860 comprise diffuse large B-cell lymphoma (DLBCL), 20,580 multiple myeloma (MM), 15,490 chronic lymphocytic leukemia /small lymphocytic lymphoma (CLL/SLL), 14,900 follicular lymphoma (FL), 8,510 Hodgkin’s lymphoma (HL), 6,000 marginal zone lymphomas (MZL) (including the three subtypes: extranodal marginal zone of mucosa-associated lymphoid tissue [MALT], nodal marginal zone, and splenic marginal zone), and 3,730 mantle cell lymphomas (MCL), as the major subtypes. With the exclusion of HL, 32,520 deaths are expected in 2009 in the US as a result of these neoplasms.

Diagnosis of these neoplasms relies mostly on the pathologic examination of biopsy material, be it either of an incisional or excisional biopsy of a suspect lymph node, a fine needle aspirate of a suspect lymph node (as yet to be considered adequate for initial diagnosis, unless it is the only safe option), or a bone marrow aspirate. Unlike other cancers, rarely are other biopsy/surgical procedures performed prior to the initiation of treatment, thus limiting the amount of tissue available for diagnostic and prognostic purposes. CGI has optimized the utility of array CGH so that it can be routinely applied to the study of a range of specimen types including formalin-fixed paraffin-embedded (FFPE) specimens, often the only specimen available for analysis.

Source: http://cancergenetics.com/cgi-research/cgh-microarray/ UMatBA is a Registered Trademark of CGI

PubMed Articles [19707 Associated PubMed Articles listed on BioPortfolio]

Genomic and molecular characterization of a novel quorum sensing molecule in Bacillus licheniformis.

Quorum sensing molecules (QSMs) are involved in the regulation of complicated processes helping bacterial populations respond to changes in their cell-density. Although the QS gene cluster (comQXPA) h...

Induction of IL-10 cytokine and the suppression of T cell proliferation by specific peptides from red cell band 3 and in vivo effects of these peptides on autoimmune hemolytic anemia in NZB mice.

The anion channel protein band 3 is the main target of the pathogenic red blood cells (RBC) autoantibodies in New Zealand black (NZB) mice. CD4 T cells from NZB mice with autoimmune hemolytic anemia r...

A CZT-based blood counter for quantitative molecular imaging.

Robust quantitative analysis in positron emission tomography (PET) and in single-photon emission computed tomography (SPECT) typically requires the time-activity curve as an input function for the pha...

Nonradioactive quantification of autophagic protein degradation with L-azidohomoalanine labeling.

At present, several assays that use radioisotope labeling to quantify the degradation of long-lived proteins have been developed to measure autophagic flux. Here, we describe a nonradioactive pulse-ch...

Fullerene C60 Penetration into Leukemic Cells and Its Photoinduced Cytotoxic Effects.

Fullerene C60 as a representative of carbon nanocompounds is suggested to be promising agent for application in photodynamic therapy due to its unique physicochemical properties. The goal of this stud...

Demonstration of Logic Operations in High-Performance RRAM Crossbar Array Fabricated by Atomic Layer Deposition Technique.

In this paper, resistive random access memory (RRAM)-based crossbar arrays with the cell structure of Pt/[AlO y /HfO x ] m /TiN were fabricated by using atomic layer deposition (ALD) technique. The RR...

Methanethiosulfonate derivatives as ligands of the STAT3-SH2 domain.

With the aim to discover new STAT3 direct inhibitors, potentially useful as anticancer agents, a set of methanethiosulfonate drug hybrids were synthesized. The in vitro tests showed that all the thios...

Design, synthesis and docking study of novel coumarin ligands as potential selective acetylcholinesterase inhibitors.

New coumaryl-thiazole derivatives with the acetamide moiety as a linker between the alkyl chains and/or the heterocycle nucleus were synthesized and in vitro tested as acetylcholinesterase (AChE) inhi...

Synthesis of new pyridothienopyrimidinone derivatives as Pim-1 inhibitors.

Four series of pyridothienopyrimidin-4-one derivatives were designed and prepared to improve the pim-1 inhibitory activity of the previously reported thieno[2,3-b]pyridines. Significant improvement in...

Priming increases the anti-tumor effect and therapeutic window of (177)Lu-octreotate in nude mice bearing human small intestine neuroendocrine tumor GOT1.

(177)Lu-[DOTA(0), Tyr(3)]-octreotate ((177)Lu-octreotate) is used for treatment of patients with somatostatin receptor (SSTR) expressing neuroendocrine tumors. However, complete tumor remission is rar...

News Articles [6456 Associated News Articles listed on BioPortfolio]

[Articles] Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3

Abbreviated rituximab-dose-dense chemotherapy plus R-MAD plus BEAM and autologous stem-cell transplantation reduced the risk of treatment failure compared with full course rituximab-dose-dense chemoth...

Tracing the origins of relapse in acute myeloid leukaemia to stem cells

In acute myeloid leukaemia, long-term survival is poor as most patients relapse despite achieving remission. Historically, the failure of therapy has been thought to be due to mutations that produce d...

Mantle Cell LymphomaGlobal API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 [Report Updated: 30052017] Prices from USD $1700

DelveInsight's Report, Mantle Cell LymphomaGlobal API Manufacturers, Marketed and Phase III Drugs Landscape, 2016, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipel...

Mesa Labs Announces New Logo

LAKEWOOD, Colo., July 9, 2012 /PRNewswire/ -- Mesa Laboratories (NASDAQ:MLAB), a Lakewood, CO based manufacturer of electronic instruments and disposables, is announcing that it has developed a n...

Breast Biopsy Market by Product [Vacuum Assisted Biopsy VAB, Core Needle Biopsy CNB and Fine Needle Aspiration Biopsy FNAB], Image Guided Technology MRIGuided Biopsy, Ultrasound Guided Biopsy, Mammography Guided Stereotactic Biopsy, CTGuided Biopsy and En

Breast biopsy is a preliminary test that detects the area of an abnormal tissue growth or diagnoses the presence of cancerous cells. Defects or abnormalities are detected in the cell with the help of ...

Mersana Therapeutics Raises $27M to Advance Fleximer® Antibody-drug Conjugates

CAMBRIDGE, Mass., July 31, 2012 /PRNewswire/ -- Mersana Therapeutics, Inc., a biopharmaceutical company developing its Fleximer®  antibody-drug  conjugate (ADC) platform and pipeli...

Graft Versus Host Disease GVHD Epidemiology Insights2023 EU5 [Report Updated: 30052017] Prices from USD $1488

DelveInsight's Graft versus Host Disease GVHD Epidemiology Insights, 2023EU5 report provides an overview of the disease and global historical and forecasted epidemiological data for the diagnosed inc...

VIDEO: SightLife Surgical begins growing endothelial cells in Seattle

NEWPORT BEACH, Calif. ― At the OCTANe Ophthalmology Technology Summit, Monty Montoya, president and CEO of SightLife Surgical, updates the progress of bringing Shigeru Kinoshita, MD, PhD’s, endoth...

As One Type of Esophageal Cancer Declines, Another Rises Sharply

Even as the incidence of esophageal squamous cell carcinoma (ESCC) continues to decline in most countries, the incidence of esophageal adenocarcinoma (EAC) is rising to at least a comparable extent, a...

GBT's sickle cell therapy gets PRIME designation

Events [0 Results]

None

Companies [468 Associated Companies listed on BioPortfolio]

NantCell, Inc.

NantCell, an entity controlled by Dr. Patrick Soon-Shiong, is an immuno-oncology company focused on the discovery of innovative antibody, T cell and NK cell based treatments by de...

Repare Therapeutics Inc.

Repare is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. Its approach integrates insights from several fields of cell b...

Rubius Therapeutics

Red-Cell Therapeutics™ are genetically engineered, enucleated red cells that provide allogeneic, off-the-shelf therapies to patients across multiple therapeutic areas. RCT ad...

Meridian Compensation Partners, LLC

Meridian Compensation Partners is a leader in charting the course for executive compensation and corporate governance success. Meridian helps clients navigate through challenging ...

Unum Therapeutics Inc.

Unum Therapeutics uses its proprietary Antibody-Coupled T cell Receptor (ACTR) technology in combination with tumor-targeting antibodies, which is designed to activate the bodyâ...

Checkmate Pharmaceuticals, Inc.

Checkmate Pharmaceuticals is a research and development company pursuing a novel approach to specifically activating the innate arm of the immune system to recognize and ultimatel...

Selexis SA and TeneoBio, Inc.

Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology a...

Eureka Therapeutics Inc.

Eureka Therapeutics Inc. is a privately held biotechnology company, headquartered in the San Francisco Bay area, focused on developing first-in-class T cell immunotherapies for he...

ACEA Biosciences

ACEA Biosciences, founded in 2002, is a privately held biotechnology company located in San Diego, California. ACEA is developing a broad biosensor platform based on proprietary microelectronic techno...

National Stem Cell Foundation

The National Stem Cell Foundation (NSCF) is a charitable 501(c)3 organization that funds adult stem cell and regenerative medicine research to accelerate treatment options, advoca...

Clinical Trials [5747 Associated Clinical Trials listed on BioPortfolio]

Study of Efficacy and Safety of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment

An international, multicenter, single arm Phase II trial to determine the efficacy, safety and quality of life of pazopanib treatment after previous therapy with immune checkpoint treatmen...

Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma

The objective of this study is to evaluate the efficacy and safety of radiation therapy combined with anti-PD-1 antibody SHR-1210 followed by surgery in treating patients with resectable e...

Observational Study to Evaluate Hematopoietic Progenitor Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma

Prospective, multicenter, observational registry of myeloma patients undergoing hematopoietic progenitor cell mobilization for upfront autologous transplantation.

Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)

This is an open-label, non-controlled, non-randomized, phase I dose-finding, of Cabometyx + Avelumab, to establish safety, feasibility, and the maximum tolerated dose (MTD) or Recommended ...

Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CHOP) Plus Metformin in Diffuse Large-B-cell Lymphoma

Evaluation of the safety and effectiveness of metformin as an adjunct to RCHOP chemotherapy for patients with newly diagnosed diffuse large-B cell lymphoma

Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders

A significant number of patients with hematologic malignancies need a hematopoietic stem cell transplant (HSCT) to be cured. Only about 50% of these patients have a fully matched donor, th...

Ultrasound Guided Transversus Abdominis Plane(TAP) Block in Intensive Care Unit

The Transversus Abdominis Block (TAP) block is known to be an effective means of reducing patient pain after abdominal surgery. In the meantime, the general TAP block has been studied in p...

Breast PET Feasibility

Breast PET may be able to help in the diagnostic pathway in patients to determine which ones need to go on to have a second look ultrasound +/- biopsy and those who need to be sent for MRI...

GPC3-T2-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression

The third generation of CAR-T cells that target GPC3 (GPC3-T2-CAR-T cell)have been constructed and their anti-HCC function has been verified by multiple in vitro and in vivo studies.Clinic...

A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies

This is a multicenter, open-label Phase 1 study of acalabrutinib, a selective and irreversible Bruton's tyrosine kinase inhibitor, in Japanese adult patients with advanced B-cell malignanc...

Videos

None available.

Medical and Biotech [MESH] Definitions

Glycoproteins expressed on all mature T-cells, thymocytes, and a subset of mature B-cells. Antibodies specific for CD5 can enhance T-cell receptor-mediated T-cell activation. The B-cell-specific molecule CD72 is a natural ligand for CD5. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)

Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.

A focal malformation resembling a neoplasm, composed of an overgrowth of mature cells and tissues that normally occur in the affected area.

Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.

Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.

Quick Search
Advertisement
 

Relevant Topic

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

review and buy MatBA - Mature B-cell neoplasm array market research data and corporate reports here

Channels Quicklinks